At this year’s Congress of the International Headache Society (IHC), migraine takes center stage. Entitled “Dawn of new headache treatments”, the meeting will give an emphasis to novel, targeted, molecular migraine treatments, as well as other emerging therapies.
Cutting edge data in basic and clinical headache research will be presented. There will be teaching courses, plenary sessions, industry symposia, exhibitions, poster sessions and much more.
Of note are two teaching courses on migraine: “Migraine comorbidities and the challenges they add to diagnosis and management”, and “Biomarkers of migraine body fluids”. One exciting plenary session asks why many drugs and devices for migraine are successful while those developed for pain fail. A series of “One Topic, Two Views” sessions addresses controversial or debated topics in headache research. One debate not to miss is on the mechanism of action for the efficacy of CGRP monoclonal antibodies.
If you are curious about the reason behind the higher prevalence of migraine in females than in males, see the parallel session on genetic and hormonal factors that could contribute to this.
To get more details on the program of the 19th IHC, visit the official website here.